Jonathon Vallejo

897 citations
31 papers · 530 · h-index 12

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • CAR-T cell therapy research
  • Statistics and Probability top 5%
    • Statistical Methods in Clinical Trials

Papers in

  • Oncology 15
    • Cancer Immunotherapy and Biomarkers 6
    • CAR-T cell therapy research 4
  • Hematology 13
    • Acute Myeloid Leukemia Research 9
    • Chronic Myeloid Leukemia Treatments 4
Co-authors
Richard Pazdur (21 shared papers)Julia A. Beaver (9 shared papers)Marc R. Theoret (18 shared papers)Erin Larkins (5 shared papers)Harpreet Singh (5 shared papers)Pallavi S. Mishra‐Kalyani (5 shared papers)Rajeshwari Sridhara (5 shared papers)Shenghui Tang (6 shared papers)
Journals
Journal of Clinical Oncology (10 papers)Clinical Cancer Research (9 papers)The Oncologist (5 papers)Blood (3 papers)JNCI Journal of the National Cancer Institute (1 paper)
Partner nations
United StatesThailandSpain

In The Last Decade

Jonathon Vallejo

25 papers receiving 518 citations

Peers

Jonathon Vallejo
Comparison fields: 5 of 65
  • Oncology 309
  • Statistics and Probability 68
  • Hematology 84
  • Genetics 51
  • Cancer Research 72
Replace Jeanne Fourie Zirkelbach with:
Jeanne Fourie Zirkelbach United States
Pierre Squifflet Belgium
S. Swann United States
Meredith K. Chuk United States
Martha MacLean Canada
Ratislav Bahleda France
Hedwig M. Blommestein Netherlands
Gwynn Ison United States
Rebecca S. Tidwell United States
M N Chang United States
Jonathon Vallejo relative to Jeanne Fourie Zirkelbach United States Jeanne Fourie Zirkelbach's profile →
Citations per field
00.5×2×3×
Jeanne Fourie Zirkelbach · 1×
Citations per year

Countries citing papers authored by Jonathon Vallejo

Since Specialization
Citations

This map shows the geographic impact of Jonathon Vallejo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathon Vallejo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathon Vallejo more than expected).

Fields of papers citing papers by Jonathon Vallejo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathon Vallejo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathon Vallejo. The network helps show where Jonathon Vallejo may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathon Vallejo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathon Vallejo Line = papers co-authored together Jonathon Vallejo links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.

#Work
1
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
The Oncologist ·Luckson Mathieu, Sujay Shah, Lee H. Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodríguez, Pallavi S. Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh
2021102
2
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
Journal of Clinical Oncology ·Jeanne Fourie Zirkelbach, Mirat Shah, Jonathon Vallejo, Joyce Cheng, Amal Ayyoub, Jiang Liu, Rachel Hudson, Rajeshwari Sridhara, Gwynn Ison, Laleh Amiri‐Kordestani, Shenghui Tang, Thomas Gwise, Atiqur Rahman, Richard Pazdur, Marc R. Theoret
202297
3
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia
The Oncologist ·Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, Lei Nie, Ann T. Farrell, Kirsten B. Goldberg, Amy E. McKee, Richard Pazdur
201844
4
Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
Journal of Clinical Oncology ·Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima, Yi Ren, Pallavi S. Mishra‐Kalyani, Erin Larkins, Paz J. Vellanki, Nicole Drezner, Luckson Mathieu, Martha Donoghue, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh
202237
5
Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.
Journal of Clinical Oncology ·Erica C. Nakajima, Yi Ren, Jonathon Vallejo, Oladimeji Akinboro, Pallavi S. Mishra‐Kalyani, Erin Larkins, Nicole Drezner, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh
202237
6
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial
The Oncologist ·Dianne Pulte, Haiyan Chen, Lauren Price, Ramadevi Gudi, Hongshan Li, Ólanrewaju O. Okusanya, Lian Ma, Lisa Rodríguez, Jonathon Vallejo, Kelly J. Norsworthy, R. Angelo de Claro, Marc R. Theoret, Richard Pazdur
202232
7
US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017
The Lancet Oncology ·Mallorie H. Fiero, Jessica Roydhouse, Jonathon Vallejo, Bellinda L. King‐Kallimanis, Paul G. Kluetz, Rajeshwari Sridhara
201930
8
Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.
Journal of Clinical Oncology ·Oladimeji Akinboro, Jonathon Vallejo, Pallavi S. Mishra‐Kalyani, Erin Larkins, Nicole Drezner, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh
202125
9
Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016
JNCI Journal of the National Cancer Institute ·Jiaxi Zhou, Jonathon Vallejo, Paul G. Kluetz, Richard Pazdur, Tamy Kim, Patricia Keegan, Ann T. Farrell, Julia A. Beaver, Rajeshwari Sridhara
201820
10
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy
The Oncologist ·Robert Q. Le, Xin Wang, Hongfei Zhang, Hongshan Li, Donna Przepiorka, Jonathon Vallejo, Rupert W. Leong, Lian Ma, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Angelo De Claro
202217
11
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
Clinical Cancer Research ·Ashley Woods, Kelly J. Norsworthy, Xin Wang, Jonathon Vallejo, Edwin C.Y. Chow, Ruo‐Jing Li, Jielin Sun, Rosane Charlab, Xiling Jiang, Richard Pazdur, Marc R. Theoret, R. Angelo de Claro
202316
12
FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy
Clinical Cancer Research ·Emily Y. Jen, Xin Wang, Meng Li, Hongshan Li, Shwu‐Luan Lee, Nina Ni, Donna Przepiorka, Jonathon Vallejo, Rupert W. Leong, Lian Ma, Brenda J. Gehrke, Sherita McLamore, Marc R. Theoret, R. Angelo de Claro
202214
13
FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI).
Journal of Clinical Oncology ·Elaine Chang, Yutao Gong, Jonathon Vallejo, Qi Liu, Luckson Mathieu, Brian Booth, Rajeshwari Sridhara, Julia A. Beaver, Richard Pazdur, Gideon M. Blumenthal
201911
14
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses
Journal of Clinical Oncology ·Kelly J. Norsworthy, Xin Gao, Chia‐Wen Ko, Dianne Pulte, Jiaxi Zhou, Yutao Gong, Yuan Li Shen, Jonathon Vallejo, Thomas Gwise, Rajeshwari Sridhara, Albert Deisseroth, Ann T. Farrell, R. Angelo de Claro, Gideon M. Blumenthal, Richard Pazdur
202111
15
Improving Collection and Analysis of Overall Survival Data
Clinical Cancer Research ·Lisa R. Rodriguez, Nicole Gormley, Ruixiao Lu, Anup Amatya, George D. Demetri, Keith T. Flaherty, Ruben A. Mesa, Richard Pazdur, Mikkael A. Sekeres, Minghua Shan, Steven Snapinn, Marc R. Theoret, Rukiya Umoja, Jonathon Vallejo, Nicholas J.H. Warren, Qing Xu, Kenneth C. Anderson
20248
16
Use of single-arm trials to support malignant hematology and oncology drug and biologic approvals: A 20-year FDA experience.
Journal of Clinical Oncology ·Sundeep Agrawal, Shaily Arora, Jonathon Vallejo, Thomas Gwise, Meredith K. Chuk, Laleh Amiri‐Kordestani, Richard Pazdur, Paul G. Kluetz, Julia A. Beaver
20217
17
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials
The Oncologist ·Jonathon Vallejo, Harpreet Singh, Erin Larkins, Nicole Drezner, Biagio Ricciuti, Pallavi S. Mishra‐Kalyani, Shenghui Tang, Julia A. Beaver, Mark M. Awad
20245
18
Dosage optimization in drug development: An FDA Project Optimus analysis of postmarketing requirements issued to repair the cracks.
Journal of Clinical Oncology ·Brian L. Heiss, Lili Pan, Alemayehu Y. Akalu, Jonathon Vallejo, Joyce Cheng, Pamela Balcazar, Nam Atiqur Rahman, Stacy S. Shord, Mirat Shah, Richard Pazdur, Marc R. Theoret
20234
19
[Scientific investigation in biomedicine and health sciences in Andalusia].
PubMed ·Soriguer Escofet Fj, A González-Valentín, Juan Francisco Miranda, Sabrina Doblas, Jonathon Vallejo
19963
20
FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation
Clinical Cancer Research ·Gulsum E. Pamuk, Edwin C.Y. Chow, Alexei Ionan, Haiyan Chen, Shwu‐Luan Lee, Vicky Hsu, Manuela Grimstein, Nan Zheng, Jielin Sun, Rosane Charlab, Brenda J. Gehrke, Jonathon Vallejo, Lori A. Ehrlich, R. Angelo de Claro, Marc R. Theoret
20242

About Jonathon Vallejo

Jonathon Vallejo is a scholar working on Oncology, Hematology, Genetics, Pulmonary and Respiratory Medicine and Cancer Research, having authored 31 papers that have together received 530 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (6 papers), Lung Cancer Treatments and Mutations (6 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers), Acute Lymphoblastic Leukemia research (4 papers), CAR-T cell therapy research (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). The work is most often cited by research in Oncology (309 citations), Statistics and Probability (68 citations), Hematology (84 citations), Genetics (51 citations) and Cancer Research (72 citations). Jonathon Vallejo has collaborated with scholars based in United States, Thailand and Spain. Frequent co-authors include Richard Pazdur, Julia A. Beaver, Marc R. Theoret, Erin Larkins, Harpreet Singh, Pallavi S. Mishra‐Kalyani, Rajeshwari Sridhara, Shenghui Tang, Paul G. Kluetz and Kirsten B. Goldberg. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Oncologist, Blood and JNCI Journal of the National Cancer Institute.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeanne Fourie ZirkelbachBreakdown of academic impact, for papers by Pierre SquiffletBreakdown of academic impact, for papers by S. SwannBreakdown of academic impact, for papers by Meredith K. ChukBreakdown of academic impact, for papers by Martha MacLeanBreakdown of academic impact, for papers by Ratislav BahledaBreakdown of academic impact, for papers by Hedwig M. BlommesteinBreakdown of academic impact, for papers by Gwynn IsonBreakdown of academic impact, for papers by Rebecca S. TidwellBreakdown of academic impact, for papers by M N Chang